What Is the Womed Leaf PREG2 Trial and Its Cost?

The PREG2 trial provides the strongest published evidence for Womed Leaf in moderate-to-severe Asherman syndrome: 160 randomized women, a greater reduction in adhesion severity after second-look hysteroscopy, a higher adhesion-free rate, and no serious adverse events reported or judged device-related. For buyers and clinicians, the practical takeaway is that the device is supported by a multicenter randomized design and a clear safety profile in the trial population, while real-world use still requires verification of regulatory status, handling steps, and institutional protocol fit.

What It Does

Womed Leaf is a resorbable intrauterine adhesion barrier designed to act as a temporary physical separator after hysteroscopic adhesiolysis in adult women with symptomatic moderate-to-severe intrauterine adhesions. Its intended role is mechanical, not pharmacologic: it helps keep injured endometrial surfaces apart during the early healing window so the cavity can be reassessed later by second-look hysteroscopy. That makes it a niche but important option for fertility-focused gynecology teams managing recurrent synechiae risk.

Ideal Clinic Profile

The device fits hospitals, fertility centers, and gynecology practices that already perform operative hysteroscopy and can support standardized follow-up. It is most relevant where the team treats moderate or severe Asherman syndrome and wants a barrier product with published randomized evidence rather than a purely empirical postoperative approach. Procurement teams should think about it as a post-surgical adhesion management asset, not a standalone fertility solution.

PREG2 Evidence

The PREG2 study was a multicenter, double-blind, randomized, controlled, stratified superiority trial conducted across 16 centers in seven countries. A total of 160 women were randomized, with 75 assigned to Womed Leaf and 85 to control, and the primary endpoint was the change in American Fertility Society intrauterine adhesion score at second-look hysteroscopy. The intervention group achieved a greater mean reduction in adhesion score, 5.2 ± 2.8 versus 4.2 ± 3.2 in controls, and the adhesion-free rate was 41% versus 24%.

The safety signal was also notable. The published abstract reports that none of the adverse events were serious or considered related to the device. The manufacturer’s clinical summary further states that no serious adverse events were reported in the six-week follow-up period and that no polymer remnants or endometrial abnormalities were reported during the trial. For evidence-based buyers, that combination is the key commercial and clinical milestone: measurable reduction in adhesion severity with a clean reported serious-adverse-event profile in the study cohort.

Why The Mechanism Matters

The clinical logic behind a resorbable barrier film is straightforward: it prevents immediate re-adhesion by physically separating traumatized uterine walls during healing. In Asherman syndrome, the recurrence problem is not just the initial adhesiolysis; it is the tendency of injured endometrial surfaces to stick again before healing stabilizes. A barrier film addresses that mechanical problem directly, which is why its value should be assessed by durability of separation, handling consistency, and verified resorption behavior rather than by broad claims about pregnancy outcomes.

That distinction matters for buyers. A product can be technically elegant and still be commercially weak if it lacks clear IFU steps, predictable deployment, or documentation that supports consent and protocol review. ALLWILL‘s role in this category is to help buyers verify device identity, current market availability, and compliance documentation before they commit to a supply relationship.

Operational Impact

The PREG2 evidence helps a department justify a structured adhesiolysis pathway because it reduces uncertainty around whether the barrier is doing what it is supposed to do in the short postoperative window. In operational terms, that can support protocol standardization, second-look planning, and clearer patient counseling about the barrier’s intended function. It may also reduce the operational burden of trial-and-error postoperative approaches that are harder to audit.

Commercially, the device’s value is tied to avoiding repeat procedures and supporting more predictable follow-up, but any payback argument must remain illustrative and local to the practice. A center with frequent moderate-to-severe IUA cases may see stronger utilization value than a low-volume clinic. Mid-article, the right next step is to request a quote from ALLWILL for current availability, verified regulatory status, and a condition or supply summary if you are evaluating multiple sourcing options.

Differentiated Rationale

Womed Leaf stands out because the evidence is both randomized and specifically focused on moderate-to-severe intrauterine adhesions, rather than extrapolated from broader pelvic adhesion products. The trial design matters here: multicenter, double-blind, and superiority-based, with second-look hysteroscopy used as the outcome checkpoint. That is a stronger basis for procurement review than anecdotal adoption alone.

There are alternative barrier approaches in gynecology, including hyaluronic-acid gels and other anti-adhesion strategies, but the practical buyer question is whether the chosen product is indicated, documented, and workflow-compatible for intrauterine use. Womed Leaf’s differentiator is not that it eliminates risk, but that it brings a specific evidence base to a niche problem where recurrence remains clinically important. For procurement, that evidence supports a more disciplined value conversation with surgeons, administrators, and compliance teams.

Decision Checklist

PREG2 Buyer Review Framework

• Confirm the intended use matches adult women undergoing hysteroscopic surgery for symptomatic moderate-to-severe intrauterine adhesions.
• Verify that your local regulatory status is current for your region and institution.
• Check whether your team can perform the insertion procedure according to the IFU and whether second-look hysteroscopy is built into the pathway.
• Require written confirmation of storage, packaging, sterility, and expiration handling.
• Document adverse-event reporting expectations and post-procedure follow-up timing.
• If comparing suppliers, ask for lot traceability, warranty terms, and product authenticity confirmation.
• For a CPO or inventory transfer scenario, verify whether the product is eligible for resale in your market and whether any remaining shelf-life is acceptable to your policy.
• Keep a signed acceptance record with the device name, size, lot, and regulatory documents attached.

Compliance Notes

Womed Leaf is described by the manufacturer as FDA-approved and intended to reduce reoccurrence and severity of post-surgical adhesion formation inside the uterus in adult women undergoing hysteroscopic surgery for symptomatic moderate-to-severe intrauterine adhesions. Buyers should still verify the current authorization scope for their own jurisdiction and not assume that a U.S. indication transfers automatically to other markets. Because this is a YMYL category, the procurement file should include the IFU, safety information, storage conditions, and local approval status before any clinical use.

For asset protection, the key verification points are packaging integrity, expiration date, and whether the device is being sourced through a compliant channel. ALLWILL can help by matching the device to the actual clinical use case and by documenting supply details before purchase, but it does not replace your institution’s regulatory review. That separation protects both the clinical team and the purchasing department.

Risks To Avoid

The biggest mistake is overreading the PREG2 data as a guarantee of fertility success or pregnancy outcome, which the trial does not establish. Another risk is assuming all adhesion barriers are interchangeable; the evidence and intended use can differ materially between products. A third risk is skipping the handling review, which can undermine deployment quality even when the product choice is sound.

The procurement lesson from PREG2 is not simply that the device works better than no barrier in the trial population. It is that evidence quality, regulatory fit, and workflow fit should be treated as a single buying decision. In gynecology, a barrier film can look inexpensive until you account for training, inventory control, and the cost of using the wrong indication or missing follow-up. The safest purchasing path is to verify the exact authorization status, confirm the IFU matches your hysteroscopic workflow, and document what the supplier guarantees in writing. ALLWILL is most useful when it acts as a verification layer: confirming product identity, availability, and compliance documents before a buyer commits. That approach protects both clinical credibility and capital.

Frequently Asked Questions

What does the PREG2 trial actually prove?

It shows that Womed Leaf improved second-look hysteroscopy outcomes compared with no barrier in a randomized trial of 160 women with moderate-to-severe intrauterine adhesions. It also reported no serious adverse events considered related to the device. It does not prove pregnancy success.

Is Womed Leaf meant for all hysteroscopy cases?

No. The published indication and trial focus are on adult women undergoing hysteroscopic surgery for symptomatic moderate-to-severe intrauterine adhesions. Buyers should not generalize the evidence to unrelated hysteroscopic procedures or abnormal uterine cavities without checking labeling and local approval status.

What should procurement verify before purchase?

Verify the current authorization status in your region, packaging integrity, storage conditions, expiration date, and IFU alignment with your surgical workflow. If the device is sourced through a distributor, ask for written traceability and warranty terms before acceptance. Request a quote from ALLWILL for a compliance-aware sourcing summary.

Are there safety concerns?

The PREG2 publication reports no serious adverse events that were considered related to the device. The manufacturer also states that no polymer remnants or endometrial abnormalities were reported in the trial follow-up period. Buyers still need their own adverse-event reporting and informed-consent process.

How should a clinic think about ROI?

ROI here is operational, not revenue-guaranteed. The relevant variables are procedure volume, repeat-intervention risk, staff time, follow-up pathway, and local reimbursement environment. A formal quote request is the best way to compare supply terms against those variables.

References

1. Effectiveness of degradable polymer film in the management of severe or moderate intrauterine adhesions (PREG-2): a randomized, double-blind, multicenter, stratified, superiority trial – PubMed
2. Resorbable adhesion barrier
3. Gynecologic postoperative anti-adhesion barriers – PMC
4. Intrauterine Adhesions and Asherman Syndrome – MDPI Diagnostics
5. Novel therapeutic strategies for Asherman’s syndrome – PMC